Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07224022Phase 2Not Yet Recruiting

Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer

Role: lead

NCT02008383Phase 1Completed

Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

Role: lead

NCT01661972Phase 1Completed

Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer

Role: lead

All 3 trials loaded